Enzychem Lifesciences Past Earnings Performance
Past criteria checks 0/6
Enzychem Lifesciences's earnings have been declining at an average annual rate of -6.5%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 11.9% per year.
Key information
-6.5%
Earnings growth rate
0.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 11.9% |
| Return on equity | -4.8% |
| Net Margin | -12.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Enzychem Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 76,039 | -9,326 | 12,593 | 5,434 |
| 30 Sep 23 | 59,475 | -15,518 | 12,372 | 5,319 |
| 30 Jun 23 | 45,339 | -18,195 | 10,489 | 5,639 |
| 31 Mar 23 | 35,492 | -20,849 | 9,548 | 6,101 |
| 31 Dec 22 | 26,638 | -24,934 | 9,723 | 6,558 |
| 30 Sep 22 | 26,481 | -23,730 | 10,124 | 6,960 |
| 30 Jun 22 | 26,404 | -25,386 | 10,602 | 8,283 |
| 31 Mar 22 | 24,507 | -26,443 | 10,562 | 8,560 |
| 31 Dec 21 | 22,975 | -26,923 | 10,876 | 9,501 |
| 30 Sep 21 | 20,437 | -24,318 | 10,678 | 11,248 |
| 30 Jun 21 | 19,293 | -22,610 | 9,749 | 12,868 |
| 31 Mar 21 | 21,509 | -20,061 | 9,149 | 12,539 |
| 31 Dec 20 | 25,818 | -17,443 | 7,566 | 12,865 |
| 30 Sep 20 | 30,385 | -18,626 | 6,279 | 10,990 |
| 30 Jun 20 | 33,352 | -15,561 | 6,458 | 11,200 |
| 31 Mar 20 | 32,925 | -17,432 | 6,752 | 12,580 |
| 31 Dec 19 | 31,469 | -16,444 | 7,082 | 11,443 |
| 30 Sep 19 | 30,462 | -13,977 | 6,762 | 11,991 |
| 30 Jun 19 | 30,506 | -14,050 | 6,728 | 9,887 |
| 31 Mar 19 | 31,150 | -11,280 | 6,257 | 8,932 |
| 31 Dec 18 | 31,034 | -14,420 | 8,654 | 9,526 |
| 30 Sep 18 | 32,609 | -11,981 | 8,143 | 8,392 |
| 30 Jun 18 | 29,699 | -11,374 | 7,515 | 7,341 |
| 31 Dec 17 | 26,133 | -5,666 | 4,538 | 4,199 |
Quality Earnings: A183490 is currently unprofitable.
Growing Profit Margin: A183490 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A183490 is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare A183490's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A183490 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A183490 has a negative Return on Equity (-4.83%), as it is currently unprofitable.